Dietmar Rohleder becomes CFO of Haupt Pharma AG

Rohleder takes over as Schwella focuses on production in Berlin

Dietmar Rohleder has been appointed chief financial officer of Haupt Pharma AG by the Supervisory Board with immediate effect.

Rohleder takes over responsibility for the areas of finance, accounting and controlling from the previous CFO, Norbert Schwella.
 As a member of the extended Board committee, Schwella will retain responsibilities for purchasing and IT. In addition, he will be focussing on his role as md of the Group's Berlin production company. Under his leadership, this company has undergone a radical reorganisation over the past two years and today it is Haupt Pharma’s most important site for the production of solid drugs in the OTC segment.

Rohleder has 19 years of working in a wide range of roles in Deutsche Bank's loans and corporate banking business. In 2005 he was appointed to the Board of what is now INVITA AG, where he has been responsible for managing and controlling the holding company ever since.

By appointing Mr Rohleder as the CFO to its holding company Haupt Pharma AG, INVITA AG is demonstrating its support for the strategic path the company is following with the aim of becoming the leading contract manufacturer and developer in Europe.

You may also like

Manufacturing

Bracco enters cell therapy manufacturing with microbubble-based cell selection technology

Bracco Imaging is expanding into cell therapy manufacturing with a bead-free cell selection and activation technology based on its clinically validated microbubble platform
Manufacturing

New manufacturing line from Adragos granted regulatory approval from Swissmedic

The approval of the new, state-of-the-art facility follows a comprehensive modernisation programme in 2024/2025 that has focussed on ensuring the future-readiness of the plant
Drug Delivery

How are biotech companies using microspheres to go beyond oncology?

Biotech companies are increasingly using microsphere drug delivery technology to expand advanced therapies beyond traditional cancer treatments. In oncology, microspheres (e.g. drug-eluting beads) have been used to localise chemotherapy and reduce side effects
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Drug Delivery

Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma

The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic blood-brain barrier transporter approaches. The results also suggest strong support for therapeutically relevant clinical effects of semaglutide using MetP Pharma’s DDT
Manufacturing

Freudenberg Medical launches new hydrophilic coating LUBRITEQ

The launch comes alongside a comprehensive suite of associated development and manufacturing services designed to remove commercial barriers and enable long-term, trust-based partnerships
Subscribe now